title: Soluble human CD83 ameliorates lupus in NZB/W F1 mice.
abstract: In the present study we explored the immunomodulatory potential of prokaryotically expressed soluble CD83 in the treatment of murine lupus using the NZB/W F1 mouse model. Therefore female NZB/W F1 lupus mice were treated either with sCD83 or PBS for 4 weeks. sCD83 treated mice showed a significantly delayed onset of anti-dsDNA autoantibody production when compared with the control group. Importantly, during the treatment period with sCD83 none of the mice showed elevated levels of anti-dsDNA autoantibodies. In addition, NZB/W F1 mice which received sCD83 displayed lower concentrations of anti-histone IgG autoantibodies. Furthermore, there was no difference in total IgG antibodies, indicating a modulatory role for sCD83 in the production of self-reactive antibodies without decreasing total IgG. These results indicate that administration of sCD83 has profound immune-modulatory effects on the induction of autoantibodies in NZB/W F1 lupus mice and may thus be a promising approach to interfere with autoimmunity in SLE and other autoantibody-driven diseases.
authors.affiliation: Department of Internal Medicine 3 and Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen-Nuremberg, Erlangen, Germany; Department of Internal Medicine 3, University of Technology, Dresden, Germany.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Starke
authors.forename: Alexander
authors.initials: A
authors.lastname: Steinkasserer
authors.forename: Reinhard E
authors.initials: RE
authors.lastname: Voll
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Zinser
mesh_terms: D000818:Animals; D000974:Antibodies, Antinuclear / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology*; D015703:Antigens, CD / Q000378:metabolism / Q000627:therapeutic use*; D001323:Autoantibodies / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology*; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007136:Immunoglobulins / Q000378:metabolism / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008562:Membrane Glycoproteins / Q000378:metabolism / Q000627:therapeutic use*; D051379:Mice; D008814:Mice, Inbred NZB; D010950:Plasma Cells / Q000187:drug effects / Q000276:immunology; D011994:Recombinant Proteins / Q000378:metabolism / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D000097802:CD83 Antigen
chemical_list: D000974:Antibodies, Antinuclear; D015703:Antigens, CD; D001323:Autoantibodies; D007074:Immunoglobulin G; D007136:Immunoglobulins; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins; D000097802:CD83 Antigen
keywords: ASCs; Anti-ds-DNA antibodies; B cell activating factor belonging to the TNF family; BAFF; CD83; DC; ELISA; ELISPOT; FACS; FCS; IgG; Immunomodulation; Lupus; NZB/W F1 mice; New Zealand Black and New Zealand White F1 mice; PBMC; SLE; Soluble human; antibody secreting cells; dendritic cells; double stranded DNA; dsDNA; enzyme-linked immune sorbent assay; enzyme-linked immune sorbent spot; fetal calf serum; fluorescence activated cell sorting; immunglobulin G; peripheral blood monocytes; systemic lupus erythematosus